This document outlines Pfizer's strategies and priorities moving forward. It discusses (1) focusing resources on best opportunities within Pfizer's existing portfolio, (2) broadening the geographic reach of its offerings especially in emerging Asian markets, and (3) developing partnerships to accelerate growth. Key priorities include optimizing top products like Lipitor, Lyrica, and Celebrex, investing in oncology and other disease areas, and capturing growth opportunities in established and emerging markets.
Strategic Management Case of Pfizer. From text book by David, Fred R. "Strategic Management Concepts & Cases",13 th Ed. Assignment on Strategic Management Class in Universitas Tarumanegara Post Graduate class.
Strategic Management Case of Pfizer. From text book by David, Fred R. "Strategic Management Concepts & Cases",13 th Ed. Assignment on Strategic Management Class in Universitas Tarumanegara Post Graduate class.
Pharmaceutical marketing plan case studyMohamed Magdy
Pharmaceutical Marketing Plan Case Study
I can challenge you will never see such fully fledged Pharmaceutical Marketing Plan Case Study in the internet for FREE as I did in this case study!
Click here to ENJOY it: http://www.guerrillamarketer.com/pharmaceutical-marketing-plan-case-study/
Pharmaceutical marketing plan case studyMohamed Magdy
Pharmaceutical Marketing Plan Case Study
I can challenge you will never see such fully fledged Pharmaceutical Marketing Plan Case Study in the internet for FREE as I did in this case study!
Click here to ENJOY it: http://www.guerrillamarketer.com/pharmaceutical-marketing-plan-case-study/
Financial Assets: Debit vs Equity Securities.pptxWrito-Finance
financial assets represent claim for future benefit or cash. Financial assets are formed by establishing contracts between participants. These financial assets are used for collection of huge amounts of money for business purposes.
Two major Types: Debt Securities and Equity Securities.
Debt Securities are Also known as fixed-income securities or instruments. The type of assets is formed by establishing contracts between investor and issuer of the asset.
• The first type of Debit securities is BONDS. Bonds are issued by corporations and government (both local and national government).
• The second important type of Debit security is NOTES. Apart from similarities associated with notes and bonds, notes have shorter term maturity.
• The 3rd important type of Debit security is TRESURY BILLS. These securities have short-term ranging from three months, six months, and one year. Issuer of such securities are governments.
• Above discussed debit securities are mostly issued by governments and corporations. CERTIFICATE OF DEPOSITS CDs are issued by Banks and Financial Institutions. Risk factor associated with CDs gets reduced when issued by reputable institutions or Banks.
Following are the risk attached with debt securities: Credit risk, interest rate risk and currency risk
There are no fixed maturity dates in such securities, and asset’s value is determined by company’s performance. There are two major types of equity securities: common stock and preferred stock.
Common Stock: These are simple equity securities and bear no complexities which the preferred stock bears. Holders of such securities or instrument have the voting rights when it comes to select the company’s board of director or the business decisions to be made.
Preferred Stock: Preferred stocks are sometime referred to as hybrid securities, because it contains elements of both debit security and equity security. Preferred stock confers ownership rights to security holder that is why it is equity instrument
<a href="https://www.writofinance.com/equity-securities-features-types-risk/" >Equity securities </a> as a whole is used for capital funding for companies. Companies have multiple expenses to cover. Potential growth of company is required in competitive market. So, these securities are used for capital generation, and then uses it for company’s growth.
Concluding remarks
Both are employed in business. Businesses are often established through debit securities, then what is the need for equity securities. Companies have to cover multiple expenses and expansion of business. They can also use equity instruments for repayment of debits. So, there are multiple uses for securities. As an investor, you need tools for analysis. Investment decisions are made by carefully analyzing the market. For better analysis of the stock market, investors often employ financial analysis of companies.
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...Quotidiano Piemontese
Turin Startup Ecosystem 2024
Una ricerca de il Club degli Investitori, in collaborazione con ToTeM Torino Tech Map e con il supporto della ESCP Business School e di Growth Capital
Seminar: Gender Board Diversity through Ownership NetworksGRAPE
Seminar on gender diversity spillovers through ownership networks at FAME|GRAPE. Presenting novel research. Studies in economics and management using econometrics methods.
What price will pi network be listed on exchangesDOT TECH
The rate at which pi will be listed is practically unknown. But due to speculations surrounding it the predicted rate is tends to be from 30$ — 50$.
So if you are interested in selling your pi network coins at a high rate tho. Or you can't wait till the mainnet launch in 2026. You can easily trade your pi coins with a merchant.
A merchant is someone who buys pi coins from miners and resell them to Investors looking forward to hold massive quantities till mainnet launch.
I will leave the what's app number of my personal pi vendor to trade with.
+12349014282
STREETONOMICS: Exploring the Uncharted Territories of Informal Markets throug...sameer shah
Delve into the world of STREETONOMICS, where a team of 7 enthusiasts embarks on a journey to understand unorganized markets. By engaging with a coffee street vendor and crafting questionnaires, this project uncovers valuable insights into consumer behavior and market dynamics in informal settings."
how to sell pi coins in South Korea profitably.DOT TECH
Yes. You can sell your pi network coins in South Korea or any other country, by finding a verified pi merchant
What is a verified pi merchant?
Since pi network is not launched yet on any exchange, the only way you can sell pi coins is by selling to a verified pi merchant, and this is because pi network is not launched yet on any exchange and no pre-sale or ico offerings Is done on pi.
Since there is no pre-sale, the only way exchanges can get pi is by buying from miners. So a pi merchant facilitates these transactions by acting as a bridge for both transactions.
How can i find a pi vendor/merchant?
Well for those who haven't traded with a pi merchant or who don't already have one. I will leave the what'sapp number of my personal pi merchant who i trade pi with.
Message: +12349014282 VIA Whatsapp.
#pi #sell #nigeria #pinetwork #picoins #sellpi #Nigerian #tradepi #pinetworkcoins #sellmypi
^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Duba...mayaclinic18
Whatsapp (+971581248768) Buy Abortion Pills In Dubai/ Qatar/Kuwait/Doha/Abu Dhabi/Alain/RAK City/Satwa/Al Ain/Abortion Pills For Sale In Qatar, Doha. Abu az Zuluf. Abu Thaylah. Ad Dawhah al Jadidah. Al Arish, Al Bida ash Sharqiyah, Al Ghanim, Al Ghuwariyah, Qatari, Abu Dhabi, Dubai.. WHATSAPP +971)581248768 Abortion Pills / Cytotec Tablets Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujeira, Ras Al Khaima, Umm Al Quwain., UAE, buy cytotec in Dubai– Where I can buy abortion pills in Dubai,+971582071918where I can buy abortion pills in Abudhabi +971)581248768 , where I can buy abortion pills in Sharjah,+97158207191 8where I can buy abortion pills in Ajman, +971)581248768 where I can buy abortion pills in Umm al Quwain +971)581248768 , where I can buy abortion pills in Fujairah +971)581248768 , where I can buy abortion pills in Ras al Khaimah +971)581248768 , where I can buy abortion pills in Alain+971)581248768 , where I can buy abortion pills in UAE +971)581248768 we are providing cytotec 200mg abortion pill in dubai, uae.Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman
how to sell pi coins effectively (from 50 - 100k pi)DOT TECH
Anywhere in the world, including Africa, America, and Europe, you can sell Pi Network Coins online and receive cash through online payment options.
Pi has not yet been launched on any exchange because we are currently using the confined Mainnet. The planned launch date for Pi is June 28, 2026.
Reselling to investors who want to hold until the mainnet launch in 2026 is currently the sole way to sell.
Consequently, right now. All you need to do is select the right pi network provider.
Who is a pi merchant?
An individual who buys coins from miners on the pi network and resells them to investors hoping to hang onto them until the mainnet is launched is known as a pi merchant.
debuts.
I'll provide you the what'sapp number.
+12349014282
What website can I sell pi coins securely.DOT TECH
Currently there are no website or exchange that allow buying or selling of pi coins..
But you can still easily sell pi coins, by reselling it to exchanges/crypto whales interested in holding thousands of pi coins before the mainnet launch.
Who is a pi merchant?
A pi merchant is someone who buys pi coins from miners and resell to these crypto whales and holders of pi..
This is because pi network is not doing any pre-sale. The only way exchanges can get pi is by buying from miners and pi merchants stands in between the miners and the exchanges.
How can I sell my pi coins?
Selling pi coins is really easy, but first you need to migrate to mainnet wallet before you can do that. I will leave the what'sapp contact of my personal pi merchant to trade with.
+12349014282
2. Elemental Economics - Mineral demand.pdfNeal Brewster
After this second you should be able to: Explain the main determinants of demand for any mineral product, and their relative importance; recognise and explain how demand for any product is likely to change with economic activity; recognise and explain the roles of technology and relative prices in influencing demand; be able to explain the differences between the rates of growth of demand for different products.
Pfizer at Cowen and Company 28th Annual Health Care Conference
1. Our Path Forward
Joe Feczko
Senior Vice President & Chief Medical Officer
2. Forward-Looking Statements
Our discussions at this meeting will include forward-looking statements.
Actual results could differ materially from those projected in the forward-
looking statements. The factors that could cause actual results to differ
are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our
reports on Form 10-Q and Form 8-K.
These reports are available on our website at www.pfizer.com in the
quot;Investors—SEC Filingsquot; section.
3. The Forces at Work in Healthcare Today
ty in
ng Socie orld
in
ances gy Agi
Adv ed W
found Technolo Develop
Pr o nd Risi
ence a
Sci ng M
in D iddle
eve
lopi Class
Info Reg
Exp rmatio ions ng
n
l
New osion &
Med
ia
m Health US
eris
m ca
Conso re Plans
n su
Co lidatin
g
Shift in Who
“ Owns” the D
ata
Transp
a
Cost an rency of Affordability
d Quali
ty
4. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets
5. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets
6. Disease Area Priorities
Invest to Win
First or High Market High
Best in Class Growth Unmet Need
Oncology
Pain
Immunology / Inflammation
Diabetes / Obesity
Alzheimer’s Disease
Schizophrenia
8. Projected 15–20 Phase 3 Starts 2008–2009
PF-3187207 PF-885706 – GERD PF-868554 PF-734200
– Glaucoma – HCV – Diabetes
PF-299804 – Cancer
CP-751871 PF-4194471 PF-4522625
PH-797804 – RA
– Lung Cancer – HIV – Seasonal Flu
NMEs IV sulopenem/Oral
PF-4383119 CP-690550 UK-453061
sulopenem pro-drug
– OA Pain – RA – HIV
– Bacterial Infections
PD-200390
– Insomnia
apixaban – VTE PF-4383119
treatment & ACS – Chronic Pain
axitinib – RCC & tremelimumab – CRC
New Lung
S,S-reboxetine – DPN
Indications
9. Potential New Indications Expected
To Drive Value
Colorectal
es
nu
ve
Non Small Cell Lung
Re
Hepatocellular Carcinoma
Breast
Renal Cell Carcinoma & Gastrointestinal Stromal Tumor
Time
10. Projected 15–20 Submissions 2010–2012
axitinib – Pancreatic Cancer Zithromax/chloroquine PF-734200 – Diabetes
– Malaria
S,S-reboxetine PD-200390 – Insomnia
– Fibromyalgia PF-299804 – Cancer
CP-751871
CP-945598 – Obesity PF-885706 – GERD – 3rd Line NSCLC
NMEs PD-332334 – GAD PF-4522625 – Seasonal Flu PF-4383119 – OA Pain
IV sulopenem / Oral PH-797804 – RA CP-690550 – RA
sulopenem pro-drug
PF-868554 – HCV
– Bacterial Infections
PF-4194471 – HIV
UK-453061 – HIV
axitinib – 1st Line S,S-reboxetine – DPN
nd
NSCLC & 2 Line RCC CP-690550 – Psoriasis
apixaban – VTE PF-4383119
New Treatment, AF & Acute – Chronic Pain
Coronary Syndrome
Indications
/
11. Steps to Improve Execution
Focus Resources
Identify Winners Early
on Best
Opportunities
Improve Clinical Trial Design to Increase
Improve Clinical Probability of a Positive Result
Trial Execution
Improve Cycle Times
13. Lipitor: Maintaining Leadership Under
Intense Competition
2008 Focus
Lipitor 2007 Worldwide Sales
Reinforce differentiation with
U.S.
Japan/Asia
compelling body of clinical
$7.8B
$1.5B
and outcomes evidence
(-6%)
(+7%)
Drive activities targeted at
Canada/
new and continuing patients
Latin
America/
Africa/
Maintain and leverage
Middle East
access
$1.3B
(+9%)
Communicate data from
Europe
Lipitor’s strong clinical
$3.0B
program
(-3%)
Source: IMS MAT 4Q2007
14. Global Lyrica Forward Plan:
Differentiate, Grow and Expand
2007 2008 +
Core Indications Strengthen Core and Expand
Restless
Legs
Syndrome
Epilepsy
Neuropathic
Neuropathic
Pain
Pain
GAD Post Op
Epilepsy Pain
Fibro
Fibromyalgia
GAD
15. Celebrex:
Preserve Today & Set the Stage for Growth
Strengthen
Repair the Patient- Optimize
Near-Term Understanding of
Physician Dialogue Execution
Efficacy & Safety
Completion of Large Safety Studies
Mid-Term
(CONDOR, PRECISION)
16. Chantix: For Smokers Motivated to Quit
45M Smokers 25M Smokers
in the U.S. Motivated to Quit
Control
Immature
Takers
Quitters
26%
25%
11.7M
Desire to Quit
Chantix
Target
MD/Rx-
Defiant Dependent
Smokers Quitters
20% 29%
13.0M
Openness to Medical Intervention
17. Sutent: The Bedrock of
Our Oncology Portfolio
U.S. Potential New Indications
mRCC Patient Share – 1st Line Expected to Drive Value
70%
60%
CRC
53%
50%
es
nu
40%
ve
NSCLC
Re
HCC
30%
Nexavar, 25%
BC
20%
cytokine, 11%
10%
Torisel, 7% RCC / GIST
Other, 5%
0%
J FMAMJ J ASOND
Time
2007
Source: ImpactRx
18. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets
19. The Opportunity
Global Pharmaceutical Sales ($ billions USD)
$898
CAGR
“Established”
$576
11% Market Is:
$523
Established Big
Products
$271 Fast growing
(Near-Post
LOE) Profitable
Innovative
4%
$375
$305
Products
(Pre-LOE)
2006 2012
* Excludes Africa/Middle East market.
Source: Datamonitor; EvaluatePharma; analyst reports.
20. The Market Is Not Homogenous,
Three Distinct Market Segments
Branded Emerging Markets
Branded Traditional Markets
IP-Driven Markets
Source: Datamonitor; EvaluatePharma; analyst reports.
21. Our Competitive Advantage =
Value Creation
Leverage
Strengths & Capabilities Our Product
Portfolio
Strong brand recognition
Track record of proven efficacy
Become a
and safety
World Leader
Strong book of business today in in Product
established products Enhancements and
Reformulation
Current portfolio about 4%
of market
Broad and deep commercial
infrastructure around the world
Pursue
Excellence in Pharmaceutical Opportunities in
“Niche” Markets
Sciences
Enhancing our value proposition
State-of-the-art manufacturing
processes and technologies Intensify Late
Stage Lifecycle
Planning
22. Our Goal – Outpace Market Growth
Increase
Emphasis on
1 Our Existing
Portfolio
Broaden the
Geographic
2 Reach of Our
Offerings
Develop
Partnerships
3 to Accelerate
Our Pace
23. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets
24. Right Geographies
#2 Europe
$13.3B
7.0% Share
#1 U.S. #4 Africa/ #1 Japan
#1 Asia
Middle East
$25.5B $3.7B
9.2% Share $2.6B
$0.4B 6.4% Share
5.5% Share
5.8% Share
#1 Latin
America
$1.4B
6.1% Share
The Powerful Forces of Globalization Play to Our Strength
Source: IMS MAT 4Q2007
25. Right Products
New In-Line Established
(glipizide) Extended Release Tablets
Dynastat ®
IV/IM
(parecoxib sidico injectable)
26. The Emerging Asian Markets Opportunity
Today 2012 Projection 2017 Projection
7–9%
6%
4%
$47B $79B $111B
Market Pfizer
Source: Projections based upon IMS Market Prognosis March 2007 & Internal Analysis (excludes Japan, Australia,
New Zealand)
27. Pfizer Well-Positioned and Investing
for Growth in Emerging Asian Markets
Asia Footprint People
Significant 2007 Sales Programs to develop and
Growth retain talent across markets
#1 Rank in Asia Strong cadre of very
experienced managers
Regional support footprint
in Hong Kong with cross- Three-quarters of
talent local
functional capabilities
Regional management team
Marketing and sales
together for nearly 10 years
infrastructure in all countries
Reputation as a Good Partner, Corporate Citizen and Employer
Source: IMS MAT 4Q2007 (excludes Japan, Australia, New Zealand)
28. Capturing Global Advantage –
Building Out Today’s Presence
R&D Manufacturing
$300 million investment in Manufacturing sites and experience
South Korea across Asia
R&D facility in China First trigeneration power plant in
Singapore – an environmental-
Establish incubators to aid Asian
friendly energy source
start-ups
New Asia R&D head based out of
Shanghai and reporting to M. Mackay
Business Development
Asia strategy founded on organic, internally driven growth
Business development opportunities also exist to
supplement growth and hedge against risk
New head of regional and local business development
based out of Hong Kong
29. Asia Strategy
Reinforce market leadership in the region,
grow market share from 4% to 7–9%
#1 pharma company in China, grow
market share from ~2% to ~8–11%
Goals Drive Korea to $1 billion business
Top 3 in fast-growing Asian
oncology market
Capture global advantage
30. Right
Products
Right
Business
Models
Right
Geographies
31. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets
32. Our Path Forward
Joe Feczko
Senior Vice President & Chief Medical Officer